Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Endocrinology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/en.142.1.370PMID 11145600
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.

  2000cited by this paper
• Sustained suppression of Fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells

  1999cited by this paper
• Induction of Apoptosis and Inhibition of Cell Proliferation bysurvivin Gene Targeting*

  1998cited by this paper
• Cell cycle changes associated with formation of Pt-DNA adducts in human ovarian carcinoma cells with different cisplatin sensitivity.

  1997cited by this paper
• The c‐IAP‐1 and c‐IAP‐2 proteins are direct inhibitors of specific caspases

  1997cited by this paper
• A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

  1997cited by this paper
• X-linked IAP is a direct inhibitor of cell-death proteases

  1997cited by this paper
• A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors.

  1996cited by this paper
• Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes

  1996cited by this paper
• BCL‐2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy

  1996cited by this paper
• Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors.

  1996cited by this paper
• The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma.

  1996cited by this paper
• Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.

  1996cited by this paper
• Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.

  1996cited by this paper
• bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas.

  1996cited by this paper
• DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines

  1996cited by this paper
• Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome.

  1996cited by this paper
• The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy.

  1995cited by this paper
• The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.

  1995cited by this paper
• Mechanisms and genes of cellular suicide

  1995cited by this paper
• Prostaglandins mediate the stimulation of deoxyribonucleic acid synthesis by transforming growth factor alpha in hen granulosa cells during ovarian follicular development.

  1995cited by this paper
• The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins.

  1995cited by this paper
• Chemotherapy‐Induced Apoptosis in Epithelial Ovarian Cancers

  1995cited by this paper
• Apoptosis in the pathogenesis and treatment of disease

  1995cited by this paper
• Bcl-2 and the regulation of programmed cell death

  1994cited by this paper
• Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.

  1994cited by this paper
• Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line.

  1994cited by this paper
• Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators.

  1994cited by this paper
• Apoptosis. Its significance in cancer and cancer Therapy

  1994cited by this paper
• An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs

  1994cited by this paper
• An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif

  1993cited by this paper
• Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

  1992cited by this paper
• Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells.

  1992cited by this paper
• Drug-target interactions: only the first step in the commitment to a programmed cell death?

  1991cited by this paper
• Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin.

  1990cited by this paper
• Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia.

  1990cited by this paper
• Mechanisms of resistance to cisplatin and alkylating agents.

  1989cited by this paper
• Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

  1988cited by this paper
• Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

  1987cited by this paper
• Structural aspects of platinum anticancer drug interactions with DNA

  1987cited by this paper
• Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA.

  1986cited by this paper
• Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.

  1985cited by this paper
• Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.

  1985cited by this paper
• Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.

  1985cited by this paper

• IAPs in cancers: molecular mechanisms, clinical prognostic value, and translational therapeutic potential

  2026cites this paper
• Proto-oncogene c-Myb potentiates cisplatin resistance of ovarian cancer cells by downregulating lncRNA NKILA and modulating cancer stemness and LIN28A-let7 axis

  2024cites this paper
• Gestational choriocarcinoma

  2023cites this paper
• Circulating and Endometrial Tissue microRNA Markers Associated with Endometrial Cancer Diagnosis, Prognosis, and Response to Treatment

  2023cites this paper
• Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells

  2023cites this paper
• Prohibitin 1 interacts with p53 in the regulation of mitochondrial dynamics and chemoresistance in gynecologic cancers

  2022cites this paper
• Subcellular localization of X-linked inhibitor of apoptosis protein (XIAP) in cancer: Does that matter?

  2022cites this paper
• Therapeutics Targeting the Core Apoptotic Machinery

  2021cites this paper
• Down-Regulating the Expression of miRNA-21 Inhibits the Glucose Metabolism of A549/DDP Cells and Promotes Cell Death Through the PI3K/AKT/mTOR/HIF-1α Pathway

  2021cites this paper
• The Prognostic Significance of the Signaling Proteins: PTEN, P85α, ATM and XIAP in Primary Ovarian Cancer

  2021cites this paper
• The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance

  2021cites this paper
• High temperature requirement A1 in cancer: biomarker and therapeutic target

  2021cites this paper
• Nitric Oxide Synthase Potentiates the Resistance of Cancer Cell Lines to Anticancer Chemotherapeutics.

  2021cites this paper
• Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy

  2021cites this paper
• Postpartum breast cancer progression is driven by semaphorin 7a mediated invasion and survival

  2020cites this paper
• Identification of hub genes associated with RNAi-induced silencing of XIAP through targeted proteomics approach in MCF7 cells

  2020cites this paper
• The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy

  2020cites this paper
• DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN–WEE1 Signaling

  2020cites this paper
• Understanding and Targeting Apoptotic Pathways in Ovarian Cancer

  2019cites this paper
• Cysteine metabolism and pancreatic neuroendocrine tumors (PNETs) chemoresistance

  2019cites this paper
• Human HLA-F adjacent transcript 10 promotes the formation of cancer initiating cells and cisplatin resistance in bladder cancer

  2018cites this paper
• Co-expression of XIAP and CIAP1 Play Synergistic Effect on Patient’s Prognosis in Head and Neck Cancer

  2018cites this paper
• Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute.

  2018cites this paper
• MiR-744-5p inducing cell death by directly targeting HNRNPC and NFIX in ovarian cancer cells

  2018cites this paper
• Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer

  2018cites this paper
• Inhibition of XIAP increases carboplatin sensitivity in ovarian cancer

  2018cites this paper
• Cysteine uptake capacity is a relevant mechanism of resistance to platinum salts, in ovarian cancer

  2018cites this paper
• Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells*

  2017cites this paper
• HtrA1 Down‐regulation Induces Cisplatin Resistance in Colon Cancer by Increasing XIAP and Activating PI3K/Akt Pathway

  2017cites this paper
• Genomic profile in gestational and non-gestational choriocarcinomas.

  2017cites this paper
• Co-Expression of XIAP and CIAP1 Play Synergistic Effect on PatientâÂÂs Prognosis in Head and Neck Cancer

  2016cites this paper
• Investigation on tissue specific effects of pro-apoptotic micro RNAs revealed miR-147b as a potential biomarker in ovarian cancer prognosis

  2016cites this paper
• Engineering Novel TNFα-armed Oncolytic Viruses for Combination Immunotherapy with SMAC Mimetics

  2016cites this paper
• Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies

  2016cites this paper
• Mitochondrial dynamics regulating chemoresistance in gynecological cancers

  2015cites this paper
• Oncogenes associated with drug resistance in ovarian cancer

  2015cites this paper
• Silencing XIAP suppresses osteosarcoma cell growth, and enhances the sensitivity of osteosarcoma cells to doxorubicin and cisplatin.

  2015cites this paper
• THE ROLE AND REGULATION of MITOCHONDRIAL DYNAMICS IN CISPLATIN RESISTANCE IN HUMAN GYNECOLOGIC CANCER CELLS

  2015cites this paper
• shRNA Depletion of cIAP1 Sensitizes Human Ovarian Cancer Cells to Anticancer Agent-Induced Apoptosis

  2015cites this paper
• Downregulation of MACC1 expression enhances cisplatin sensitivity in SKOV-3/DDP cells.

  2015cites this paper
• “Ziziphus jujuba”: A red fruit with promising anticancer activities

  2015cites this paper
• Anthocyanins From the Fruit of Vitis coignetiae Pulliat Potentiate the Cisplatin Activity by Inhibiting PI3K/Akt Signaling Pathways in Human Gastric Cancer Cells

  2015cites this paper
• Mechanisms of apoptosis in ovarian cancer: The small molecule targeting

  2015cites this paper
• p53 Is Required for Cisplatin-induced Processing of the Mitochondrial Fusion Protein L-Opa1 That Is Mediated by the Mitochondrial Metallopeptidase Oma1 in Gynecologic Cancers*

  2014cites this paper
• HAX1 regulates E3 ubiquitin ligase activity of cIAPs by promoting their dimerization

  2014cites this paper
• Gelsolin regulates cisplatin sensitivity in human head‐and‐neck cancer

  2014cites this paper
• Small molecule modulators of protein-protein interactions: selected case studies.

  2014cites this paper
• Soluble‐E‐cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers

  2014cites this paper
• Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis

  2014cites this paper
• X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary

  2014cites this paper
• β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNK

  2013cites this paper
• Effect of amine and carboxyl functionalization of sub-micrometric MCM-41 spheres on controlled release of cisplatin

  2013cites this paper
• Protein Kinase G-Iα Hyperactivation and VASP Phosphorylation in Promoting Ovarian Cancer Cell Migration and Platinum Resistance

  2013cites this paper
• The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells

  2013cites this paper
• Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0152 in human plasma using solid-phase extraction.

  2013cites this paper
• Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation

  2013cites this paper
• Enhancement of cisplatin-induced apoptosis by β-elemene in resistant human ovarian cancer cells

  2013cites this paper
• Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.

  2013cites this paper
• Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer.

  2013cites this paper
• p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax.

  2013cites this paper
• Tumor suppressor genes associated with drug resistance in ovarian cancer (review).

  2013cites this paper
• Integrating immune cell functions and apoptosis-based therapies for the treatment of ovarian cancer

  2013cites this paper
• Positron Emission Tomography Imaging of Platinum Resistant Ovarian Cancer And Drug Modulation

  2012cites this paper
• Influence of De Novo designed peptides on cancer development: a novel approach to skin cancer therapy

  2012cites this paper
• HtrA1 sensitizes ovarian cancer cells to cisplatin‐induced cytotoxicity by targeting XIAP for degradation

  2012cites this paper
• Molecular Targeted Therapy in Ovarian Cancer

  2011cites this paper
• Platinum Complexes for the Treatment of Cancer

  2011cites this paper
• TRIM32 Protein Sensitizes Cells to Tumor Necrosis Factor (TNFα)-induced Apoptosis via Its RING Domain-dependent E3 Ligase Activity against X-linked Inhibitor of Apoptosis (XIAP)*

  2011cites this paper
• IRES-mediated translation of cellular messenger RNA operates in eIF2α- independent manner during stress

  2011cites this paper
• Signalling Towards IRES

  2011cites this paper
• DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation.

  2011cites this paper
• Involvement of ARLTS1 in chemotherapy and apoptosis in ovarian cancer cell line

  2011cites this paper
• Tumor and Stem Cell Biology D Np 63 a Confers Tumor Cell Resistance to Cisplatin through the AKT 1 Transcriptional Regulation

  2011cites this paper
• D Np63 a Confers Tumor Cell Resistance to Cisplatin through the AKT1 Transcriptional Regulation

  2011cites this paper
• DNA-triggered synthesis and bioactivity of proapoptotic peptides.

  2011cites this paper
• Chemosensitization of tumors by resveratrol

  2011cites this paper
• Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines

  2011cites this paper
• Potential Therapeutic Benefits of Strategies Directed to Mitochondria

  2010cites this paper
• Target genes suitable for silencing approaches and protein product interference in ovarian epithelial cancer.

  2010cites this paper
• Small-molecule pan-IAP antagonists: a patent review

  2010cites this paper
• Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.

  2010cites this paper
• Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells

  2010cites this paper
• Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein

  2010cites this paper
• Cisplatin resistance: preclinical findings and clinical implications.

  2010cites this paper
• Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells

  2010cites this paper
• Resistance to chemotherapy and hormone therapy in endometrial cancer.

  2009cites this paper
• Cell survival and apoptosis‐related molecules in cancer cells in effusions: A comprehensive review

  2009cites this paper
• 7-(O)-Carboxymethyl daidzein conjugated to N-t-Boc-hexylenediamine: A novel compound capable of inducing cell death in epithelial ovarian cancer stem cells

  2009cites this paper
• Review Article Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor- kappa B

  2009cites this paper
• Arguments en faveur de l'existence d'une activité pro-apoptotique des lamellarines vis-à-vis des cellules tumorales par ciblage mitochondrial

  2009cites this paper
• XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.

  2009cites this paper
• MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition

  2009cites this paper
• Die TRAIL-Suszeptibilität humaner Melanomzellen : Bedeutung des Tumorprogressionsstadiums und Modulation durch Immunsuppressiva

  2009cites this paper
• Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B.

  2009cites this paper
• Targeting IAP (inhibitor of apoptosis) proteins for therapeutic intervention in tumors.

  2008cites this paper
• Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer

  2008cites this paper
• The RING domain of cIAP1 mediates the degradation of RING-bearing inhibitor of apoptosis proteins by distinct pathways.

  2008cites this paper
• BRCA1 185delAG mutant protein, BRAt, amplifies caspase-mediated apoptosis and maspin expression in ovarian cells

  2008cites this paper
• [Effects of apoptosis protein XIAP inhibitor on the apoptosis and sensitivity of chemotherapy in A549 cell.].

  2008cites this paper
• Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function

  2008cites this paper